Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Oct 14, 2026

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functionsGenerate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total o
Press release cover image

Oct 13, 2026

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functionsGenerate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total o
Press release cover image

Oct 13, 2026

Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery

A spin-out focused on AI-enabled decoding of the deliveromeProprietary synthetic biology platform identifies conjugates that target RNA medicines beyond the liver, with initial focus on renovascular diseaseRound co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras CapitalCAMBRIDGE, England & TEL AVIV, Israel--(BUSINESS WIRE)--Undecimal Bio (“Undecimal”), a platform biotechnology company advancing targeted delivery
Press release cover image

Oct 12, 2026

Hankang Pharmaceutical Reaches Key Milestone in AI-Driven Small Molecule Discovery Program for Oncology and Autoimmune Diseases

Program supported by a Tianjin Municipal Major Special Project marks Hankang’s move from development partner to originator of Class 1 innovative drugs.TIANJIN, China | October 2026Tianjin Hankang Pharmaceutical & Biotechnology CompanyLimited ("Hankang") announced that its program "AI LargeModel-Based Discovery and Development of Innovative Small Molecule Drugs forOncology and Autoimmune Diseases" has recently completed key studies andachieved its interim objectives. The program was selected
Press release cover image

Oct 9, 2026

Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with biopharma company GSK following a successful technology evaluation.Under the collaboration, GSK will gain access to Chai's platform, including its protein folding and design models, to power discovery efforts across GSK’s pipeline.In the evaluation, Chai’s models generated designs to GSK targets, zero-shot without target-specific training. GSK
An open research notebook in a dimly lit lab, showcasing notes on neuropsychiatric datasets.

Oct 7, 2026

Gaithersburg's BullFrog AI Hits Key Milestones in Depression Drug Discovery Program With Top-5 Global Pharma

BullFrog AI, based in Gaithersburg, Maryland, has reached significant milestones in its collaboration with a leading global pharmaceutical company, focusing on drug discovery for major depressive disorder (MDD) using advanced AI technologies.On October 6, 2026, the company revealed that its proprietary AI and machine learning platform successfully identified and prioritized new therapeutic targets for MDD by leveraging unique neuropsychiatric multi-omic datasets. Vin Singh, the CEO, emphasized t
Press release cover image

Oct 7, 2026

Carterra Advances Lab-In-The-Loop Drug Discovery Through New Scientific Collaboration

Bringing together scientific and technical expertise to advance development of hardware and software aimed at enabling a new wave of AI-driven, autonomous biologics discoverySALT LAKE CITY--(BUSINESS WIRE)--Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR™) platforms for antibody and small molecule drug discovery, today announced a research collaboration with AstraZeneca to develop hardware and software aimed at advancing lab-in-the loop drug discovery. The effo
Press release cover image

Oct 7, 2026

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the resultsNew QIAGEN Discovery Platform extends AI into drug discovery workflowsQIAGEN builds on more than 25 years of biomedical knowledge, with QDI tools used by around 150,000 usersVENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--$QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabiliti
Press release cover image

Oct 6, 2026

XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling

This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy prediction models to accelerate drug development.Validating this infrastructure, XtalPi announced the advancement of six proprietary preclinical programs targeting complex diseases, with the first one reaching NHP data in just 7 months; in utilizing opt
Press release cover image

Oct 6, 2026

Cresset launches Flare AI Client, helping computational chemists complete hours of work in minutes

Scientistscan now connect company-approved AI providers such as Claude Code and GitHubCopilot directly to Flare, helping teams set up, execute, and analyze complexcomputational chemistry workflows in minutes not hours.CAMBRIDGE, UK, October 6th 2026– Drug discovery teams are under pressure to evaluate more molecules, deliverresults faster and achieve more with the resources they already have. AI canhelp, but scientists do not want another standalone agent to learn, validateand govern. They need
Press release cover image

Oct 5, 2026

Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases

Strategic collaboration combines Italfarmaco’s leadership in HDAC biology and therapeutic development with VeriSIM Life’s Mechanistic AI drug discovery platform to create differentiated therapeutic assetsSAN FRANCISCO & MILAN--(BUSINESS WIRE)--Italfarmaco S.p.A., a global pharmaceutical company with established expertise in histone deacetylase (HDAC) biology and therapeutic development, and VeriSIM Life, an AI-enabled drug discovery and development company, today announced a strategic collab
Press release cover image

Oct 2, 2026

Exobiosphere to Become the First Commercial Customer of Outpost's New Space Factories, Bringing Microgravity Drug Discovery to Orbit and Back

Space biotech leader Exobiosphere will fly its Orbital High-Throughput System as the first customer module on Outpost's Space Factories platform — pairing repeatable microgravity access with reliable Earth return.LOS ANGELES, Oct. 2, 2026 /PRNewswire/ -- Outpost Technologies Corporation ("Outpost"), the orbital logistics company building reusable vehicles that return cargo from space to precise locations on Earth, today announced an agreement making Exobiosphere the first announced customer of O